Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.
240 medicines
-
Memantine and Donepezil Being discontinued 2 products · updated June 15, 2026
Neurology
Product Availability Expected supply / notes Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3)
Amneal PharmaceuticalsDiscontinuation of the manufacture of the drug
Being discontinued · June 15, 2026Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3)
Amneal PharmaceuticalsDiscontinuation of the manufacture of the drug
Being discontinued · June 15, 2026 -
Dacomitinib Being discontinued 3 products · updated June 8, 2026
Oncology
Product Availability Expected supply / notes Vizimpro, Tablet, 15 mg (NDC 0069-0197-30)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · June 8, 2026Vizimpro, Tablet, 30 mg (NDC 0069-1198-30)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · June 8, 2026Vizimpro, Tablet, 45 mg (NDC 0069-2299-30)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · June 8, 2026 -
Leflunomide Being discontinued 5 products · updated June 8, 2026
Rheumatology
Product Availability Expected supply / notes Leflunomide, Tablet, 10 mg (NDC 0955-1735-30)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · June 8, 2026Arava, Tablet, 20 mg (NDC 0088-2161-30)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · June 8, 2026Arava, Tablet, 100 mg (NDC 0088-2162-33)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · June 8, 2026Arava, Tablet, 10 mg (NDC 0088-2160-30)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · June 8, 2026Leflunomide, Tablet, 20 mg (NDC 0955-1737-30)
Sanofi-Aventis U.S. LLCDiscontinuation of the manufacture of the drug
Being discontinued · June 8, 2026 -
Semaglutide Being discontinued 3 products · updated June 4, 2026
Endocrinology/Metabolism
Product Availability Expected supply / notes Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)
Novo Nordisk, Inc.Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
Being discontinued · June 4, 2026Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)
Novo Nordisk, Inc.Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
Being discontinued · June 4, 2026Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)
Novo Nordisk, Inc.Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
Being discontinued · June 4, 2026 -
Alcohol Being discontinued 1 product · updated May 27, 2026
Cardiovascular
Product Availability Expected supply / notes Dehydrated Alcohol, Injection, Solution, 1 mL/1 mL (10 pack) (NDC 16729-710-45)
Accord Healthcare Inc.Accord is transitioning to the 5-pack configuration (NDC 16729-710-53).
Being discontinued · May 27, 2026 -
Alteplase Being discontinued 1 product · updated May 21, 2026
Cardiovascular, Hematology, Neurology
Product Availability Expected supply / notes Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE * 100 mL in 1 VIAL, SINGLE USE (NDC 50242-085-27)
Genentech, IncDiscontinuation of the 100mg vial configuration
Being discontinued · May 21, 2026 -
Iron Sucrose Being discontinued 1 product · updated May 21, 2026
Hematology
Product Availability Expected supply / notes Iron Sucrose, Injection, 50 mg/2.5 mL (NDC 67457-957-99)
Mylan Institutional, a Viatris CompanyA business decision has been made to discontinue of 2.5mL presentation only. Continuity of supply is forecasted across all other presentations of Iron Sucrose: 67457-639-10 Iron Sucrose 20mg/mL 10mL SDV 5PK 67457-638-10 Iron Sucrose 20mg/mL 5mL SDV 10PK 67457-638-25 Iron Sucrose 20mg/mL 5mL SDV 25PK.
Being discontinued · May 21, 2026 -
Activated Charcoal Being discontinued 5 products · updated May 15, 2026
Other
Product Availability Expected supply / notes Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · May 15, 2026Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · May 15, 2026Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · May 15, 2026Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · May 15, 2026Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74)
Padagis US LLCDiscontinuation of the manufacture of the drug
Being discontinued · May 15, 2026 -
Sulconazole Nitrate Being discontinued 3 products · updated May 8, 2026
Dermatology
Product Availability Expected supply / notes Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05)
Journey Medical CorporationDiscontinuation of the manufacture of the drug
Being discontinued · May 8, 2026Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30)
Journey Medical CorporationDiscontinuation of the manufacture of the drug
Being discontinued · May 8, 2026Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30)
Journey Medical CorporationDiscontinuation of the manufacture of the drug. Manufactured for JG Pharma
Being discontinued · May 8, 2026 -
Icatibant Being discontinued 2 products · updated May 7, 2026
Hematology
Product Availability Expected supply / notes Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93)
Fresenius Kabi USA, LLCDiscontinuation of the manufacturer of the drug
Being discontinued · May 7, 2026Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86)
Fresenius Kabi USA, LLCDiscontinuation of the manufacturer of the drug
Being discontinued · May 7, 2026 -
Lamotrigine Being discontinued 6 products · updated April 29, 2026
Neurology
Product Availability Expected supply / notes Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)
Par Health, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 29, 2026Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)
Par Health, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 29, 2026Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)
Par Health, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 29, 2026Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)
Par Health, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 29, 2026Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)
Par Health, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 29, 2026Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)
Par Health, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 29, 2026 -
Crinecerfont Being discontinued 1 product · updated April 28, 2026
Endocrinology/Metabolism
Product Availability Expected supply / notes Crenessity, Capsule, 25 mg (NDC 70370-5025-1)
Neurocrine Biosciences, Inc.Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).
Being discontinued · April 28, 2026 -
Etravirine Being discontinued 2 products · updated April 28, 2026
Antiviral
Product Availability Expected supply / notes Etravirine, Tablet, 100 mg (NDC 10147-0570-1)
Janssen Research and DevelopmentDiscontinuation of the manufacture of the drug
Being discontinued · April 28, 2026Intelence, Tablet, 100 mg (NDC 59676-570-01)
Janssen Research and DevelopmentDiscontinuation of the manufacture of the drug
Being discontinued · April 28, 2026 -
Palbociclib Being discontinued 2 products · updated April 22, 2026
Oncology
Product Availability Expected supply / notes Ibrance, Capsule, 75 mg (NDC 0069-0187-21)
Pfizer Inc.Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured.
Being discontinued · April 22, 2026Ibrance, Capsule, 100 mg (NDC 0069-0188-21)
Pfizer Inc.Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.
Being discontinued · April 22, 2026 -
Tiagabine Hydrochloride Being discontinued 4 products · updated April 15, 2026
Neurology
Product Availability Expected supply / notes Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56)
Teva Pharmaceuticals USA, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 15, 2026Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56)
Teva Pharmaceuticals USA, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 15, 2026Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56)
Teva Pharmaceuticals USA, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 15, 2026Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56)
Teva Pharmaceuticals USA, Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 15, 2026 -
Nitroglycerin Being discontinued 1 product · updated April 14, 2026
Analgesia/Addiction
Product Availability Expected supply / notes Rectiv, Ointment, 0.4% (NDC 58914-301-80)
AbbVie Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 14, 2026 -
Nitrofurantoin Being discontinued 1 product · updated April 10, 2026
Anti-Infective, Other
Product Availability Expected supply / notes Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9)
Amneal PharmaceuticalsDiscontinuation of the manufacture of the drug
Being discontinued · April 10, 2026 -
Azithromycin Dihydrate Being discontinued 3 products · updated April 9, 2026
Anti-Infective
Product Availability Expected supply / notes Zithromax, Tablet, 250 mg (NDC 0069-4061-01)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 9, 2026Zithromax, Tablet, 500 mg (NDC 0069-3070-30)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 9, 2026Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83)
Pfizer Inc.Discontinuation of the manufacture of the drug.
Being discontinued · January 20, 2026 -
Aprepitant Being discontinued 1 product · updated April 8, 2026
Gastroenterology
Product Availability Expected supply / notes Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)
Merck Sharp & Dohme LLCTo be discontinued in approximately early-September 2026.
Being discontinued · April 8, 2026 -
Fosaprepitant Being discontinued 1 product · updated April 8, 2026
Gastroenterology
Product Availability Expected supply / notes Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10)
Fresenius Kabi USA, LLCDiscontinuation of the manufacture of the drug
Being discontinued · April 8, 2026 -
Idelalisib Being discontinued 2 products · updated April 7, 2026
Oncology
Product Availability Expected supply / notes Zydelig, Tablet, 150 mg (NDC 61958-1702-1)
Gilead Sciences, Inc.Discontinuation in the manufacturing of the drug
Being discontinued · April 7, 2026Zydelig, Tablet, 100 mg (NDC 61958-1701-1)
Gilead Sciences, Inc.Discontinuation in the manufacturing of the drug
Being discontinued · April 7, 2026 -
Ursodiol Being discontinued 1 product · updated April 6, 2026
Other
Product Availability Expected supply / notes Ursodiol, Capsule, 300 mg (NDC 64380-844-06)
Strides Pharma Inc.Discontinuation of the manufacture of the drug
Being discontinued · April 6, 2026 -
Icosapent Ethyl Being discontinued 2 products · updated April 1, 2026
Cardiovascular
Product Availability Expected supply / notes Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12)
Apotex Corp.Discontinuation of the manufacture of the drug
Being discontinued · April 1, 2026Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1)
Apotex Corp.Discontinuation of the manufacture of the drug
Being discontinued · April 1, 2026 -
Daspone Being discontinued 1 product · updated March 27, 2026
Dermatology
Product Availability Expected supply / notes Dapsone, Gel, 7.5% (NDC 69238-1627-6)
Amneal PharmaceuticalsDiscontinuation of the manufacture of the drug
Being discontinued · March 27, 2026 -
Progesterone Being discontinued 1 product · updated March 27, 2026
Urology
Product Availability Expected supply / notes Crinone, Vaginal Gel, 4% (NDC 0023-6150-04)
AbbVie Inc.Discontinuation of the manufacture of the drug
Being discontinued · March 27, 2026 -
Tazemetostat Being discontinued 1 product · updated March 27, 2026
Oncology
Product Availability Expected supply / notes Tazverik, Tablet, 200 mg (NDC 72607-100-00)
Epizyme, Inc. (An Ipsen Company)Discontinuation of the manufacture of the drug product
Being discontinued · March 27, 2026 -
Clindamycin Palmitate Hydrochloride Being discontinued 2 products · updated March 26, 2026
Anti-Infective
Product Availability Expected supply / notes Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)
Amneal PharmaceuticalsDiscontinuation of the manufacture of the drug
Being discontinued · March 26, 2026Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)
Amneal PharmaceuticalsDiscontinuation of the manufacture of the drug
Being discontinued · February 27, 2026 -
Lincomycin Hydrochloride Being discontinued 3 products · updated March 26, 2026
Anti-Infective
Product Availability Expected supply / notes Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6)
XGen Pharmaceuticals DJB, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · March 26, 2026Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2)
XGen Pharmaceuticals DJB, Inc.A business decision was made to discontinue manufacture of the drug.
Being discontinued · March 26, 2026Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04)
Pfizer Inc.Discontinuation of the manufacture of the drug
Being discontinued · February 25, 2026 -
Nebivolol Hydrochloride Being discontinued 16 products · updated March 25, 2026
Cardiovascular
Product Availability Expected supply / notes Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-90)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30)
Torrent Pharmaceuticals LimitedDiscontinuation of the manufacture of the drug
Being discontinued · March 25, 2026 -
Ivabradine Being discontinued 3 products · updated March 24, 2026
Cardiovascular
Product Availability Expected supply / notes Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60)
Amgen Inc.Discontinuation of the manufacture of the drug product
Being discontinued · March 24, 2026Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60)
Amgen Inc.Discontinuation of the manufacture of the drug product
Being discontinued · March 24, 2026Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28)
Amgen Inc.Discontinuation of the manufacture of the drug product
Being discontinued · March 24, 2026
Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.
Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.